RTP Mobile Logo
Virtual Molecular Tumor Board: Identification of New and Emerging Genomic Alterations in Metastatic Non-Small Cell Lung Cancer (Webinar Proceedings)
Released October 2020

Proceedings from the second in a 3-part webinar series. Featuring perspectives from Drs Alexander E Drilon, Andrew McKenzie and Milan Radovich. (Video Program)

CE Disclosures and Faculty Information

    This activity is intended for medical oncologists, hematology-oncology fellows, pathologists and other allied healthcare professionals involved in the treatment of lung cancer and other solid tumors.


    • Appraise recent FDA approvals, investigator perspectives and available data related to the management of metastatic non-small cell lung cancer (NSCLC) with EGFR or BRAF mutations, and discern how this information should be applied to patient care.
    • Recognize the spectrum and prevalence of emerging biomarkers for treatment (eg, RET and NTRK fusions, MET exon 14 mutations, HER2 and ROS1 alterations) in metastatic NSCLC, and develop an understanding of available and investigational therapies that might benefit patients harboring each of these abnormalities.
    • Recall available genetic testing platforms for biomarker assessment for patients with NSCLC.
    • Consider recent FDA approvals, expert perspectives and available clinical trial data to determine the role of immune checkpoint inhibitors in the treatment of NSCLC.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CME credit is no longer available for this issue

    This CME activity consists of a video component.
    CME credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Alexander E Drilon, MD
    Chief, Early Drug Development Service
    Associate Attending Physician
    Thoracic Oncology Service
    Memorial Sloan Kettering Cancer Center
    New York, New York

    Advisory Committee and Consulting Agreements: AbbVie Inc, ArcherDX Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene, BerGenBio ASA, Blueprint Medicines, Elevation Oncology, EMD Serono Inc, Exelixis Inc, Genentech, a member of the Roche Group, Helsinn Healthcare SA, Hengrui Therapeutics Inc, Ignyta Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Medendi Inc, MJH Life Sciences, Monopteros Therapeutics, MORE Health Inc, Novartis, Pfizer Inc, Remedica Ltd, Roche Laboratories Inc, Takeda Oncology, TP Therapeutics Inc, Tyra Biosciences, Verastem Inc; Contracted Research: Exelixis Inc, Foundation Medicine, GlaxoSmithKline, Pfizer Inc, PharmaMar, Taiho Oncology Inc, Teva Oncology; Food and Beverage: Merck, Puma Biotechnology Inc; Royalties: Wolters Kluwer; Other: Boehringer Ingelheim Pharmaceuticals Inc, Merus BV.

    Andrew McKenzie, PhD
    Director, Personalized Medicine
    Sarah Cannon Research Institute
    Nashville, Tennessee

    No financial interests or affiliations to disclose.

    Milan Radovich, PhD
    Associate Professor
    IU Health Vice President for Oncology Genomics
    Indiana University Melvin and Bren Simon Comprehensive Cancer Center
    Indianapolis, Indiana

    Contracted Research: Boston Biomedical Inc, Lilly; Ownership Interest: Immunomedics Inc, LifeOmic Health LLC, Tyme Inc.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Verastem Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

    This activity is supported by an educational grant from Lilly.

    Release date: October 2020
    Expiration date: October 2021

Acknowledge and close

Watch video
(WIFI is recommended for best performance):

Part 1: Case Presentations

Part 2: Beyond EGFR, BRAF and ALK — Actionable Biomarkers in NSCLC

Part 3: Case Presentations

Select Publications